Antitope Ltd. Announces Antibody Research Agreement with Fusion Antibodies Ltd. (Belfast, UK)
Cambridge UK, 10th July 2008 - Antitope Ltd. ("Antitope") today announced a research agreement with Fusion Antibodies Limited ("Fusion") for the generation of therapeutic monoclonal antibodies. The research program will use Antitope's proprietary Composite Human AntibodyTM technology for the humanization of Fusion's proprietary lead antibody.
"We are delighted to be working with Fusion to produce humanized antibodies with low immunogenic potential" said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. "This partnership builds on Antitope's expertise in humanized antibodies devoid of T cell epitopes with Fusion's skills and innovation in monoclonal antibodies and new cancer therapies."
"Antitope has excellent complementary technology to Fusion and therefore is an ideal partner for the pre-clinical design and formulation of our lead drugs" said Prof. Jim Johnston, Chief Scientific Officer of Fusion Antibodies. "We have developed a very successful working relationship for this and, we anticipate, for our future pipeline antibody therapeutics."
About Antitope
Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary Composite Human AntibodyTM technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in antibodies/proteins. Antitope is a privately-held company and has established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope, please visit http://www.antitope.co.uk/.
About Fusion Antibodies Limited
Fusion Antibodies' R&D focus is in identifying tumour specific antigens and developing therapeutic antibodies to these targets. A pipeline of targets has been discovered and is presently being evaluated for therapeutic suitability. The use of an integrated and multi-disciplinary team approach to antibody drug discovery enables Fusion Antibodies to rapidly design and develop test reagents for evaluation, using its high throughput FET recombinant protein platform. The R&D is focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. For further information of Fusion Antibodies, please visit http://www.fusionantibodies.com/
For further information contact:
Dr Neil Butt
Business Development Director
Tel: +44 (0)1223 496190
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Prof Jim Johnston
CEO
Fusion Antibodies Ltd.
Tel: +44 (0)2890 432 800
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it